Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Diamedica Therapeutics ( (DMAC) ) has provided an update.
DiaMedica Therapeutics announced its financial results for the third quarter of 2025, highlighting significant progress in its clinical trials. The company completed the Part 1a dose escalation cohort of its Phase 2 trial for preeclampsia and is now enrolling for the expansion cohort, with screening for the fetal growth restriction cohort set to begin soon. Additionally, a pre-IND meeting with the U.S. FDA was held to discuss plans for a U.S. Phase 2 study in preeclampsia. The ReMEDy2 Phase 2/3 trial for acute ischemic stroke is nearing 50% enrollment of its target for interim analysis expected in the second half of 2026. DiaMedica reported $55 million in cash and investments, providing financial runway into the second half of 2027.
The most recent analyst rating on (DMAC) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Average Trading Volume: 352,996
Technical Sentiment Signal: Buy
Current Market Cap: $313.2M
Find detailed analytics on DMAC stock on TipRanks’ Stock Analysis page.